Triple-negative breast cancer developing beside a large breast cyst

Patient Info: Anonymized, Female, 60s | Stage II

Biomarkers: ER negative; PR negative; HER2 negative; Ki-67 >50%; p53 negative for overexpression, triple negative

She recovered after treatment with no clinical evidence of regional or distant recurrence.

PubMed CentralRead more →

Dramatic chemotherapy response in stage IIIB triple-negative breast cancer

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative; BRCA1-negative; BRCA2-negative; germline FLCN c.1285delC associated with Birt-Hogg-Dubé syndrome; tumor TP53 p.T150fs.

Eighteen months after surgery, she had no recurrence following a dramatic chemotherapy response, bilateral mastectomy, chest-wall radiation, and adjuvant capecitabine.

PubMed CentralRead more →

Stage IIIA breast cancer treated alongside a synchronous colon cancer

Patient Info: Anonymized, Female, 50s | Stage III

Two years after surgery, she remained well with no CT evidence of metastasis or recurrence while continuing endocrine therapy and six-monthly follow-up.

PubMed CentralRead more →

Metastatic Breast Cancer Presenting With Severe Pulmonary Hypertension

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: ER-positive; PR-positive.

Metastatic Site: bone; bone marrow

At seven months, she was doing well with a marked response on PET imaging, normalized right-heart pressures, and ongoing systemic treatment with palbociclib.

PubMed CentralRead more →

Nocardia Infection Mimicked Breast Cancer Lung Metastases

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-positive.

The lung nodules resolved with antibiotics and proved infectious rather than metastatic; she remained in good health at the last follow-up in January 2019.

PubMed CentralRead more →

Breast Cancer Survivor Story: Chemo, Double Mastectomy, Radiation, Reconstruction

Patient Info: Margaret, Female | Stage II

Biomarkers: Oncotype DX score reported around 16-18; genetic testing negative; specific inherited gene not named

As of June 2019, Margaret was in remission after Stage II IDC treated with double mastectomy, AC/Taxol chemotherapy, radiation, and reconstruction.

The Patient StoryRead more →

Stage III Triple-Negative Breast Cancer: Mary's Survivor Story

Patient Info: Mary, Female | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative., triple negative

Mary completed treatment, was declared cancer-free in February 2025, and was in remission without ongoing medication.

Our Cancer StoriesRead more →

Splenectomy Reduced Transfusion Needs in Metastatic Lobular Breast Cancer

Patient Info: Anonymized, Female, 40s | Stage Metastatic/Advanced

Biomarkers: ER positive; PR positive; HER2 negative

Metastatic Site: skin|bone|bone marrow|spleen

She remained independent through her last oncology visit 18 months after splenectomy and died 1 month later.

PubMed CentralRead more →

Stage II HER2-Positive Breast Cancer With Anti-Yo Paraneoplastic Cerebellar Degeneration

Patient Info: Anonymized, female, 50s | Stage II

Biomarkers: HER2 positive

Her severe anti-Yo paraneoplastic cerebellar syndrome did not meaningfully respond to IVIG or cancer treatment. She became wheelchair-dependent and ultimately required long-term care, with only moderate improvement in ataxia after rehabilitation.

PubMed CentralRead more →

Recurrent HER2-Positive Breast Cancer With Paraneoplastic Cerebellar Degeneration

Patient Info: Anonymized, Female, 50s

Biomarkers: ER-negative; PR-negative; HER2 3+; anti-Yo antibody positive

Her neurological symptoms continued to progress despite cancer-directed treatment; postoperative recovery was uncomplicated.

PubMed CentralRead more →

Breast cancer recurrence involving the bladder and bones

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Initial breast cancer: ER-positive, PR-positive, HER2-negative. Bladder metastasis: ER-positive, PR-negative, HER2 1+.

Metastatic Site: bladder, bone, rectosigmoid region, anorectal region

She died in October 2016 from pulmonary haemorrhage, 47 months after metastatic disease was diagnosed.

PubMed CentralRead more →

Stage II metaplastic breast cancer in a 47-year-old man

Patient Info: Anonymized, Male, 40s | Stage II

Biomarkers: ER 1%; PR negative; HER2 negative; E-cadherin positive; p63 positive; genetic testing reported no abnormal mutations

Two years after surgery he was doing well, with only occasional pain at the mastectomy site and a negative recent mammogram of the left breast.

PubMed CentralRead more →

Triple receptor-positive neuroendocrine breast cancer in a 32-year-old woman

Patient Info: Anonymized, Female, Under 40 | Stage III

Biomarkers: ER positive; PR positive; HER2 positive; neuron-specific enolase positive; synaptophysin positive

She was stable on follow-up and was receiving adjuvant chest-wall radiation plus systemic chemotherapy and trastuzumab-based therapy.

PubMed CentralRead more →

Metastatic Breast Cancer With Liver Progression Treated Through Multiple Chemotherapy Lines

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: Initial tumor: ER 90%, HER2 3+, Ki67 15%. Liver metastasis: ER 30%

Metastatic Site: pleura, liver

After several periods of response and later liver progression, she remained on active treatment with pegylated liposomal doxorubicin.

PubMed CentralRead more →

Metastatic Lobular Breast Cancer With Long-Term Disease Control Across Multiple Therapies

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: Initial tumor: ER negative, HER2 negative, Ki67 17%. 2006 recurrence: ER 40%

Metastatic Site: pleura, liver, skin, bone

She was alive on ongoing metronomic vinorelbine with substantial disease stabilization at the most recent follow-up.

PubMed CentralRead more →

Bilateral Breast Cancers Followed by Metastatic Disease and Long Eribulin Treatment

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: Left primary: ER 90%, HER2 FISH not amplified, Ki67 25%. Right primary: ER 90%

Metastatic Site: lung, pleura, liver, bone

After pelvic bone metastases appeared in 2017, she stopped eribulin, received pelvic radiation and remained on fulvestrant treatment.

PubMed CentralRead more →

Recurrent Breast Cancer With Liver Metastases Treated Through Multiple Chemotherapy Lines

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: Initial tumor: ER positive, HER2 0. Liver metastasis: ER 100%

Metastatic Site: liver

After liver progression following 18 cycles of eribulin, she started weekly carboplatin and remained in active treatment.

PubMed CentralRead more →

Metastatic Breast Cancer Responding to Eribulin After Repeated Liver Progression

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: ER 100%, HER2 negative

Metastatic Site: bone, liver

Eribulin remained ongoing with repeated partial responses documented through 12 cycles and no need for dose reduction.

PubMed CentralRead more →

Metastatic Breast Cancer With Brain, Bone, Lung and Liver Disease Responding During Eribulin Treatment

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: Initial tumor: ER 90%, HER2 negative, Ki67 10%. Lung metastasis: ER 90%

Metastatic Site: lung, bone, brain, liver

Eribulin remained ongoing with reduced brain lesions, stable bone disease and continued shrinkage of liver metastases after prior systemic progression.

PubMed CentralRead more →

Breast Cancer: Kat's Patient Story

Patient Info: Kat

Nine months after diagnosis, she had completed radiation treatment and was looking ahead to recovery and hair regrowth.

Dana-FarberRead more →

ER/PR-positive breast cancer with bilateral ovarian metastases controlled after oophorectomy and aromatase inhibitor

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative; CK7-positive; gross cystic disease fluid protein-15-positive; CK20-negative

Metastatic Site: bilateral ovaries

After bilateral oophorectomies and aromatase inhibitor therapy, pleural effusion resolved, CEA and CA 15-3 decreased below the normal upper limit, and she remained well with no further recurrence for 40 months.

PubMed CentralRead more →

Hormone-positive breast cancer with axillary recurrence responding to hyperthermia, radiation, and chemotherapy

Patient Info: Anonymized, Female, 60s

Biomarkers: ER-positive; PR-positive; HER2-negative

The left axillary recurrence enlarged during weekly paclitaxel and radiotherapy, then became nearly flat and was assessed as a complete response 8 weeks after adding hyperthermia.

PubMed CentralRead more →

Recurrent HER2-amplified breast cancer: complete remission on trastuzumab-based therapy

Patient Info: Anonymized, Female, 40s | Stage Metastatic/Advanced

Biomarkers: Primary tumor was ER/PR negative and HER2 not amplified. Recurrent lymph-node disease became ER/PR positive and HER2 amplified by FISH.

Metastatic Site: left axillary and infraclavicular lymph nodes

After HER2-amplified nodal recurrence, paclitaxel plus trastuzumab produced complete clinical remission; she continued trastuzumab monotherapy with tolerable neuropathy.

PubMed CentralRead more →